Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.
| Date | Candidate | Mechanism of action | Indication | Route | Modality | Development stage | Note | |
|---|---|---|---|---|---|---|---|---|
| 03/01/19 | GEM066 | Selective STAT3 inhibitor (DNA-based Decoy) | Head and neck squamous cell carcinoma and non-small cell lung cancer [including exon 20 mutations] | IV | Nucleic acids |
Pre-IND for systemic administration formulation | 1st-in-class STAT3 decoy; Suppresses binding of STAT3 to genomic DNA; Inhibits proliferation and promotes apoptosis of many cancer cells; Suppresses expression of STAT3 target genes and tumor growth in animal models; Shows increased response in combination with cetuximab and also with PD-1; Human Phase 0 study (intratumor injection); Suppresses STAT3 target genes expression with one dose Does not affect normal oral keratinocytes; Exploratory animal toxicology studies show no significant adverse effects; |
Contact |
| 03/01/19 | GEM064 | Selective inhibitor of Nav channels | Pain | Oral | Small molecule |
Preclinical | Potent and selective inhibitors for Nav 1.7/1.8 subtypes Effective in inflammatory & neuropathic pain states Exellent non-clinical ADMET profile No off-target activity, very good in vitro cardiac safety margin, non-mutagenic |
Contact |
| 02/12/19 | GEM063 | Novel 24hr ibuprofen patch | Local pain in sprains | Local | Small molecule |
Phase 1 completed | High payload: Contains 200 mg ibuprofen, Constant delivery over 24 hours, Class-leading adhesion, Water-resistant, Comfortable to wear and remove Pre-clinical safety studies were completed 2017 with no concerns/issues Phase I PK and sensitisation/irritancy studies were successfully completed in 2018 with no concerns/issues |
Contact |
| 01/11/19 | GEM009 | BET inhibitor | Cancer, RA | Oral | Small molecules |
Preclinical | Updated on January 11, 2019 More potent enzyme inhibition and anti-tumor activities compared with competitors (more potent than GSK525762A and comparble to ABBV-075). Superior safety profile than competitors (no inhibition on hERG or CYP3A4) and can be applied to RA. Easier manufacturing due to absence of asymmetric carbon. |
Contact |
| 01/11/19 | GEM003 | Selective glucocorticoid receptor agonist | RA/OA, Please refer to Note | Local | Small molecules |
Preclinical | Updated on January 11, 2019 Expected to reduce unfavorable responses of glucocorticoids by selectivity of action (transrepression>transactivation) Discontinued development for RA/OA. Available for repositioning. Possible indications: Atopic dermatitis, Psoriasis, Asthma, COPD, Inflammatory bowel disease etc. |
Contact |
| 01/11/19 | GEM002 | Kappa-opioid receptor agonist | Pain/Itching, Please refer to Note | Oral | Small molecules |
Preclinical | Updated on January 11, 2019 Discontinued development for pain because of company strategy. Available for repositioning. Possible indications: Chronic pains (Back pain, Arthritis pain, Cancer pain, Post-herpetic neuralgia, Trigeminal neuralgia etc), Pruritus, Irritable bowel syndrome |
Contact |
| 01/11/19 | GEM001 | TRPV-1 agonist | Rheumatoid Arthritis, Please refer to Note | Oral | Small molecules |
Phase 2a | Updated on January 11, 2019 Potently inhibits TNF-a production by oral administration. Discontinued development for RA. Available for repositioning. Possible indications: Neuropathic pain, Crohn’s disease, Systemic lupus erythematosus, Cachexia, Acute infectious disease, Allergy, Pyrexia, Anemia, Diabetes, Diseases related TNF-α (Colitis, Psoriasis ets.) |
Contact |
| 01/07/19 | GEM062 | Cannabinoid-releasing topical formulation (siustained release for about 24 hours) | Chronic pain, Sclerosis, Lupus, others | Topical | Small molecule |
Preclinical | Cannabinoid’s utility: nausea and vomiting during chemotherapy, chronic pain, muscle spasms, epilepsy, sclerosis, lupus, schizophrenia etc. This sustained-release topical formulation has significant potential to help treat these disorders. Preclinical efficacy demonstrated in a cutaneous lupus rodent model using AEA. |
Contact |
| 01/07/19 | GEM061 | Curcumin-releasing topical formulation (sustained release for about 24 hours) | Please refer to Note | Topical | Small molecule |
Preclinical | Indication: Osteoarthritis, CV disease, chronic inflammatory disease, vascular disease (Sickle Cell) Note: Curcumin’s utility: chronic pain, chronic inflammatory conditions such as osteoarthritis, vascular disease such as Sickle Cell and diabetes. This formulation breaks through the limitations of the poor bioavailability of curcumin with oral administration. Preclinical efficacy demonstrated in an rodent arthritis model and a rodent diabetes model. |
Contact |
| 01/07/19 | GEM060 | Nitric Oxide-releasing topical formulation (sustained release for over 48 hours) | Please refer to Note | Topical | Small molecules |
Preclinical | Indication: Acne, Atopic Dermatitis, Fungal diseases, Wound healing, Chronic rhinosinusitis, Diabetic foot ulcers, Raynaud’s Phenomenon, Middle-ear infections, Erectile dysfunction, Others Note: NO function: Regulation of the vasculature (vasodilatory), broad spectrum antimicrobial activity, anti-inflammatory, anti-oxidant, wound healing, skin cell maturation and survival etc. Human POC already shown with NO in onychomycosis, genital warts, moscullum contagiosum, pulmonary hypertension, acne, atopic dermatits (preliminary); animal POC demonstrated in over 20 peer-reviewed papers. This formulation breaks through the limitations of sustained NO (topical) delivery. |
Contact |